首页 › 免疫系统与疾病 › 宾夕法尼亚州 › Philadelphia
Philadelphia PA 免疫系统与疾病临床试验
10项针对 免疫系统与疾病的研究正在 Philadelphia及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
招募中观察性研究
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 距离 23 英里
- Christiana Care Health System-Wilmington Hospital, Wilmington · 距离 25 英里
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
招募中1 期
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
招募中3 期
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
招募中3 期
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Thomas Jefferson University, Philadelphia
Abatacept for the Treatment of Giant Cell Arteritis
招募中3 期
- University of Pennsylvania, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
招募中2 期
- Children's Hospital of Philadelphia, Philadelphia
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
招募中1/2 期
- Nemours Children's Health, Wilmington · 距离 25 英里
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
招募中1/2 期
- University of Pennsylvania, Philadelphia
其他城市的 免疫系统与疾病试验
- Washington, DC13 项研究
- New York City, NY12 项研究
- Boston, MA10 项研究
- Portland, OR9 项研究
- Atlanta, GA9 项研究
- Houston, TX9 项研究
- Los Angeles, CA8 项研究
- Cleveland, OH8 项研究
- Chicago, IL8 项研究
- Milwaukee, WI6 项研究
- Seattle, WA6 项研究
- Cedar Rapids, IA6 项研究
Philadelphia的其他研究
- 癌症（所有类型）59 项研究
- 乳腺癌56 项研究
- 非小细胞肺癌51 项研究
- 转移性癌症46 项研究
- 前列腺癌44 项研究
- 结直肠癌44 项研究
- 卵巢癌44 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 心力衰竭31 项研究
- 子宫内膜癌28 项研究
- 抑郁症26 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。